GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Green Cross Corp (XKRX:006280) » Definitions » COGS-to-Revenue

Green Cross (XKRX:006280) COGS-to-Revenue : 0.69 (As of Sep. 2024)


View and export this data going back to 1989. Start your Free Trial

What is Green Cross COGS-to-Revenue?

Green Cross's Cost of Goods Sold for the three months ended in Sep. 2024 was ₩319,380 Mil. Its Revenue for the three months ended in Sep. 2024 was ₩464,866 Mil.

Green Cross's COGS to Revenue for the three months ended in Sep. 2024 was 0.69.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Green Cross's Gross Margin % for the three months ended in Sep. 2024 was 31.30%.


Green Cross COGS-to-Revenue Historical Data

The historical data trend for Green Cross's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Green Cross COGS-to-Revenue Chart

Green Cross Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.71 0.66 0.66 0.70

Green Cross Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.74 0.76 0.69 0.69

Green Cross COGS-to-Revenue Calculation

Green Cross's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1142011.053 / 1626643.816
=0.70

Green Cross's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=319379.61 / 464865.549
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Green Cross  (XKRX:006280) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Green Cross's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 319379.61 / 464865.549
=31.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Green Cross COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Green Cross's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Green Cross Business Description

Traded in Other Exchanges
N/A
Address
303 Bojeong-Dong, Giheung-Gu, Yongin, Gyeonggi, KOR, 449-070
Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.

Green Cross Headlines

No Headlines